New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
09:03 EDTMNKMallinckrodt to present new data for Xartemis XR, Pennsaid 2%
Mallinckrodt will present new data for two of its recently approved pain medications XARTEMIS XR Extended-Release Tablets and PENNSAID 2% during the 33rd Annual Scientific Meeting of the American Pain Society to be held April 30 - May 3, 2014 in Tampa, Florida. XARTEMIS XR is an oral medication indicated for the management of acute pain severe enough to require opioid treatment in patients for whom alternative treatment options are ineffective, not tolerated or would otherwise be inadequate. It is the first and only oxycodone HCI/acetaminophen combination for acute pain with immediate- and extended-release analgesia, providing fast-acting and long-lasting pain relief with 12-hour dosing for patients. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for the treatment of the pain of osteoarthritis of the knee(s). The data to be presented on XARTEMIS XR evaluates pharmacokinetics in different populations, as well as pooled safety data from Phase III trials. The first presentation of pivotal efficacy and safety results for PENNSAID 2% in the treatment of pain for osteoarthritis of the knee will also be presented, as well as an assessment of pharmacokinetics and tolerability compared with the 1.5% PENNSAID formulation.
News For MNK From The Last 14 Days
Check below for free stories on MNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
10:16 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:49 EDTMNKMallinckrodt reinstated with an Overweight at Barclays
Subscribe for More Information
September 16, 2014
07:30 EDTMNKCRT Capital to hold a conference
2nd Annual Investor Conference to be held in Greenwich, CT on September 16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use